Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.

ABSTRACT:

Importance

Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs.

Objective

To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors.

Design, setting, and participants

This open-label, multicenter, randomized phase 2 trial was conducted in 5 Belgian hospitals and enrolled participants between March 2018 and October 2020. Patients 18 years or older with locally advanced or metastatic melanoma, renal cell carcinoma, urothelial carcinoma, head and neck squamous cell c

SUBMITTER: Spaas M 

PROVIDER: S-EPMC10326732 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature